PMID- 29269144
OWN - NLM
STAT- MEDLINE
DCOM- 20190128
LR  - 20190128
IS  - 1873-4995 (Electronic)
IS  - 0168-3659 (Print)
IS  - 0168-3659 (Linking)
VI  - 270
DP  - 2018 Jan 28
TI  - The feasibility of an encapsulated cell approach in an animal deafness model.
PG  - 275-281
LID - S0168-3659(17)31080-5 [pii]
LID - 10.1016/j.jconrel.2017.12.014 [doi]
AB  - For patients with profound hearing loss a cochlear implant (CI) is the only 
      treatment today. The function of a CI depends in part of the function and 
      survival of the remaining spiral ganglion neurons (SGN). It is well known from 
      animal models that inner ear infusion of neurotrophic factors prevents SGN 
      degeneration and maintains electrical responsiveness in deafened animals. The 
      purpose with this study was to investigate the effects of a novel encapsulated 
      cell (EC) device releasing neurotrophic factors in the deafened guinea pig. The 
      results showed that an EC device releasing glial cell line-derived neurotrophic 
      factor (GDNF) or brain-derived neurotrophic factor (BDNF) implanted for four 
      weeks in deafened guinea pigs significantly preserved the SGNs and maintained 
      their electrical responsiveness. There was a significant difference between BDNF 
      and GDNF in favour of GDNF. This study, demonstrating positive structural and 
      functional effects in the deafened inner ear, suggests that an implanted EC 
      device releasing biologically protective substances offers a feasible approach 
      for treating progressive hearing impairment.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Fransson, Anette
AU  - Fransson A
AD  - Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden. Electronic 
      address: anette.fransson@ki.se.
FAU - Tornoe, Jens
AU  - Tornoe J
AD  - NsGene A/S, 2750 Ballerup, Denmark.
FAU - Wahlberg, Lars U
AU  - Wahlberg LU
AD  - NsGene A/S, 2750 Ballerup, Denmark.
FAU - Ulfendahl, Mats
AU  - Ulfendahl M
AD  - Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20171218
PL  - Netherlands
TA  - J Control Release
JT  - Journal of controlled release : official journal of the Controlled Release 
      Society
JID - 8607908
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Glial Cell Line-Derived Neurotrophic Factor)
SB  - IM
MH  - Animals
MH  - Brain-Derived Neurotrophic Factor/*administration & dosage
MH  - Deafness/*drug therapy/physiopathology
MH  - Disease Models, Animal
MH  - *Drug Delivery Systems
MH  - Evoked Potentials, Auditory, Brain Stem
MH  - Female
MH  - Glial Cell Line-Derived Neurotrophic Factor/*administration & dosage
MH  - Guinea Pigs
MH  - Male
PMC - PMC5819869
OTO - NOTNLM
OT  - Cochlear implant
OT  - Drug delivery
OT  - EC-device
OT  - Encapsulated cells
OT  - Neurotrophic factor
OT  - Spiral ganglion neuron
EDAT- 2017/12/23 06:00
MHDA- 2019/01/29 06:00
PMCR- 2018/01/28
CRDT- 2017/12/23 06:00
PHST- 2017/08/24 00:00 [received]
PHST- 2017/12/15 00:00 [revised]
PHST- 2017/12/17 00:00 [accepted]
PHST- 2017/12/23 06:00 [pubmed]
PHST- 2019/01/29 06:00 [medline]
PHST- 2017/12/23 06:00 [entrez]
PHST- 2018/01/28 00:00 [pmc-release]
AID - S0168-3659(17)31080-5 [pii]
AID - 10.1016/j.jconrel.2017.12.014 [doi]
PST - ppublish
SO  - J Control Release. 2018 Jan 28;270:275-281. doi: 10.1016/j.jconrel.2017.12.014. 
      Epub 2017 Dec 18.